Genmab — Marts 2018
-
En af de enestående beretninger: The patient’s disease, which was considered high risk with a deletion of chromosome 17p, advanced quickly and was triple refractory 2 years after diagnosis leaving few treatment options. He was treated with daratumumab monotherapy in the SIRIUS clinical trial resulting in a stringent complete response and clearance of minimal residual disease. The duration of the patient’s clinical response is now over 3.5 years without relapse,
-
-
Interessant i øvrigt, at de mener at den immunmodulerende virkning af dara kan forstærkes ved kombination med PD-1/PD-L1 hæmmere i MM. Og Chen har jo peget på at dara kan forstærke virkningen af PD-1/PD-L1 hæmmere i lungecancer. Det bliver fremtidens par nummer 7.
-
Pauly...Jeg mangler også mit.
-
PS: Jeg rykker lige vores deltidsmedarbejder i teknikken.
-
- På dette niveau er jeg absolut ikke bange for min investering, -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind